Advertisement
News
Subscribe to MDT Magazine News

Valeant Pharmaceuticals Adds Corporate Governance Expert Abe Friedman to its Slate of Proposed Cephalon Directors

April 18, 2011 3:36 am | by Bio-Medicine.Org | Comments

MISSISSAUGA, Ontario, April 18, 2011 /- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: VRX) today filed a revised preliminary consent solicitation statement in which it named Mr. Abe M. Friedman to its slate of proposed directors in connection with its previously announced...

TOPICS:

TRTB to Launch Blue Diamond Pill Targeting Ethnic Market With Sexual Enhancement Pills

April 18, 2011 2:36 am | by Bio-Medicine.Org | Comments

LOS ANGELES, April 18, 2011 /- True 2 Beauty Inc., (Pinksheets: TRTB - News ) (the "Company") ( www.true2beautyinc.com ), a leading distributor of male and female sexual potency pills and liquid products in the United States, is pleased to announce the launch of a new, additional line of...

TOPICS:

Inovio Pharmaceuticals, Transgene and ChronTech Pharma to Collaborate on Heterologous Prime-Boost Therapeutic Vaccination Against Hepatitis C

April 18, 2011 12:35 am | by Bio-Medicine.Org | Comments

BLUE BELL, Pa., April 18, 2011 /- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today it has signed a collaboration agreement with Transgene S.A. (Euronext Paris:...

TOPICS:
Advertisement

$210M Pfizer Deal Validates Small Firm

April 17, 2011 11:33 pm | by San Diego Business Journal | Comments

Robin Jackman, Zacharon's president and CEO, is the first to admit that there aren't too many people outside the biotech world who understand the science at the core of his small company.

TOPICS:

Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and S...

April 17, 2011 10:34 pm | by Bio-Medicine.Org | Comments

MYSTIC, Conn. and DUBLIN, April 18, 2011 /- Amarin Corporation plc (Nasdaq: AMRN ), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from its ANCHOR trial for the Company's lead product...

TOPICS:

Minorities born with heart defects at higher risk of dying in early childhood than whites

April 17, 2011 9:32 pm | by EurekAlert | Comments

(University of South Florida (USF Health)) Non-Hispanic black infants born with heart defects are more likely to die within the first five years of life than their non-Hispanic white and Hispanic peers, reports a new study by researchers at the University of South Florida, Texas...

TOPICS:

High-Speed Evolution Aids Drug Development

April 17, 2011 8:36 pm | by Massachusetts Institute of Technology | Comments

A new technique can make tailor-made proteins evolve in days, not years.

La Jolla Institute identifies new therapeutic target for asthma, COPD and other lung disorders

April 17, 2011 10:33 am | by EurekAlert | Comments

(La Jolla Institute for Allergy and Immunology) Michael Croft, Ph.D., a researcher at the La Jolla Institute for Allergy & Immunology, has discovered a molecule's previously unknown role as a major trigger for airway remodeling, which impairs lung function, making the molecule a promising...

TOPICS:
Advertisement

Pharmatek Granted Approval by the DEA for Analysis of All Controlled Substances

April 17, 2011 4:35 am | by Bio-Medicine.Org | Comments

SAN DIEGO, April 17, 2011 /- Pharmatek Laboratories, Inc., a premier contract development and manufacturing organization supporting the pharmaceutical industry, announced that it has been approved by the United States Drug Enforcement Agency (DEA) for the analysis of Schedules I through V...

TOPICS:

New patient guidelines for heart devices

April 16, 2011 6:37 am | by EurekAlert | Comments

(Henry Ford Health System) A series of new guidelines for cardiac specialists has been developed to determine when heart failure patients should receive a mechanical heart-pumping device.

TOPICS:

Health care-associated infections are exacerbated by alcohol use disorders(2)

April 15, 2011 2:36 pm | by EurekAlert | Comments

(Alcoholism: Clinical & Experimental Research) Health care-associated infections (HAIs) are infections that patients acquire during their hospitalization and that were not present at the time of admission to the hospital. A new study has found that people with alcohol use disorders...

TOPICS:

MedPAC Vote Could Mean Less Innovation for Imaging Devices

April 15, 2011 2:30 pm | by U.S. Food & Drug Administration | Comments

Recommendations from the Medicare Payment Advisory Commission (MedPAC) could curtail use of medical imaging devices.

TOPICS:

eSource Guidance Doesn & #8217;t Reflect Current Practice, Industry Says

April 15, 2011 2:30 pm | by U.S. Food & Drug Administration | Comments

Manufacturers commenting on an FDA draft guidance addressing electronic data from clinical trials say the guidance is out of sync with current capabilities and practices for data capture and lacks information about the sponsor’s role in reviewing data.

TOPICS:

Alkermes' diabetes treatment boosted in Europe

April 15, 2011 1:38 pm | by Mass High Tech: The Journal of New England Technology | Comments

Alkermes Inc. has received a positive opinion from a key European regulatory committee for its experimental diabetes treatment, Bydureon. The recommendation means the drug candidate is very likely to be approved there.

TOPICS:

Health care-associated infections are exacerbated by alcohol use disorders

April 15, 2011 1:37 pm | Comments

Alcoholism: Clinical & Experimental Research

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading